MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Effects of plantar automated mechanical stimulation (AMPS) on motor symptoms of patients with advanced Parkinson’s disease: Preliminary data of a double blind randomized clinical trial

    L. Bartolomei, M. Malaguti, A. Pastore, G.M. Minicuci, N. Bonetto, S. Ferrari, M. Pellegrini (Vicenza, Italy)

    Objective: To evaluate the effect of one session treatment with autometed mechanical peripheral stimulation (AMPS) on gait and motor functions of patients with advanced Parkinson's…
  • 2016 International Congress

    Long-term safety of levodopa-carbidopa intestinal gel from an ongoing, open-label, phase 3 continued access to treatment study in advanced Parkinson’s disease patients

    R.L. Rodriguez, C. Zadikoff, A.J. Espay, V.S.C. Fung, C. Hall, W.Z. Robieson, K. Chatamra, S. Eaton, M.F. Facheris, J. Benesh (Orlando, FL, USA)

    Objective: To assess the safety and tolerability of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) in advanced Parkinson's disease…
  • 2016 International Congress

    Extended-release carbidopa-levodopa, IPX066: Dosing and efficacy with concomitant medication use in Parkinson’s disease

    S. Gupta, S. Khanna, S. Kell, R. Rubens (Hayward, CA, USA)

    Objective: Evaluate the efficacy and dosing of IPX066 in patient groups taking concomitant Parkinson's disease (PD) medication, using post hoc subgroup analyses. Background: IPX066 is…
  • 2016 International Congress

    Rasagiline treatment for sleep disorders in Parkinson’s disease (RaSPar) – Double-blinded, randomized, placebo-controlled, placebo run-in-phase, polysomnography clinical trial

    W. Schrempf, M. Fauser, K. Otto, M. Wienecke, C. Ossig, S. Brown, A. Maass, M.D. Brandt, U. Schwanebeck, X. Graehlert, H. Reichmann, A. Storch (Dresden, Germany)

    Objective: To study the effects of Rasagiline on sleep disturbances measured by polysomnographic (PSG) evaluation of sleep efficacy and secondary measures as other sleep variables,…
  • 2016 International Congress

    Efficacy of apomorphine subcutaneous injections in patients with levodopa dose failures and morning akinesia

    S.H. Isaacson (Boca Raton, FL, USA)

    Objective: To assess the effect of subcutaneous injection of apomorphine (APO) in patients with Parkinson's disease (PD)and morning akinesia who experience dose failures after their…
  • 2016 International Congress

    A clinical trials ‘charter’ to improve communication about, recruitment to and retention in Parkinson’s clinical trials

    C. Carroll, I. Tom, M. Helen, S. Jon (Plymouth, United Kingdom)

    Objective: The objective of the project was to design a durable tool, usable by clinical trial investigators and participants alike, that would improve subject retention…
  • 2016 International Congress

    Global implementation of efficacious voice treatment for Parkinson’s disease: LSVT LOUD: Germany®

    T. Brauer, H. Penner, P. Benecke, C. Fox, L. Ramig (Mainz, Germany)

    Objective: This project was designed to evaluate the implementation of an efficacious voice treatment (LSVT LOUD) developed in the USA and designed to improve speech…
  • 2016 International Congress

    RE-024: A potential phosphopantothenate replacement therapy in 2 patients with pantothenate kinase-associated neurodegeneration (PKAN)

    P. Roa, P. Stoeter, E. Perez, M. Santana (Santo Domingo, Dominican Republic)

    Objective: To evaluate the safety and potential efficacy of RE-024 in open treatment of 2 patients with PKAN. Background: PKAN is an autosomal recessive, neurodegenerative…
  • 2016 International Congress

    Chronic directional subthalamic nucleus deep brain stimulation in Parkinson’s disease – A pilot study

    P. Reker, T.A. Dembek, A. Gierich, J. Wirths, H.S. Dafsari, J. Roediger, M.T. Barbe, L. Timmermann, V. Visser-Vandewalle (Cologne, Germany)

    Objective: This pilot study aimed to assess the therapeutic potential of chronically implanted directional DBS leads in patients with Parkinson's disease. Background: The therapeutic effect…
  • 2016 International Congress

    Can stimulation of deep brain tissue improve the expression of the mouth in Parkinson’s disease patients?

    M.V. Alvarez, P.M. Grogan (San Antonio, TX, USA)

    Objective: To observe if stimulation of deep brain tissue can improve expression of the mouth in Parkinson's disease patients. Background: Masked facies or hypomimia is…
  • « Previous Page
  • 1
  • …
  • 37
  • 38
  • 39
  • 40
  • 41
  • …
  • 207
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Life expectancy with and without Parkinson’s disease in the general population
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley